Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors-Reference-Cited by-同舟云学术

Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors

Published:2024-01-12 Issue:16 Volume:20 Page:1069-1077
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Yoo Changhoon¹^ORCID,Lamarca Angela²,Choi Hye Jin³,Vogel Arndt⁴⁵,Pishvaian Michael J⁶,Goyal Lipika⁷,Ueno Makoto⁸,Märten Angela⁹,Teufel Michael¹⁰,Geng Lijiang¹¹,Morizane Chigusa¹²

Affiliation:

1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea

2. Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital, 28040 Madrid, Spain

3. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

4. Department of Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, 0625 Hannover, Germany

5. Department of Gastroenterology & Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C4, Canada

6. Department of Oncology, John Hopkins University, Washington, DC 20016, USA

7. Stanford Cancer Center, Palo Alto, CA 94305, USA

8. Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan

9. Boehringer Ingelheim International GmbH, 55218 Ingelheim am Rhein, Germany

10. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT 0687, USA

11. Boehringer Ingelheim (China) Investment Co., Shanghai 200040, China

12. Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan

Funder

Boehringer Ingelheim

Publisher

Informa UK Limited

Link